Following the outbreak of Guillain-Barré Syndrome (GBS) in Pune and four deaths and 45 cases reported in the State, public ...
BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $32 from $34 and keeps an Underperform rating on the shares.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback